UPDATE: Dougherty & Company Raises PT on Baxter International to $56

Dougherty & Company maintains its Neutral rating on Baxter International

and raises its price target on the company's shares from $53 to $56 in a research report out today. In the report, Dougherty & Company writes, "We're raising our PT to $56 (previous $53) on slightly better sentiment with pending HyQvia approvals. While we see slightly better sentiment to the Baxter story, we're still maintaining our Neutral rating on the stock until we get over the hump for some of the headwinds facing the business (i.e., tougher comps on Bioscience, weaker margins, plant shutdowns, etc.)." Shares of Baxter International are currently trading at $57.82, down 0.28% from Friday's market close.